[Combination of rituximab with combined pulse-therapy with high doses of methylprednisolone and cyclophosphamide: effects on immunomorphological and functional disturbances of the salivary glands in a patient with Sjogren's disease and MALT-lymphoma].
Vasil'ev
V I
VI
Kokosadze
N V
NV
Logvinenko
O A
OA
Nikitin
E A
EA
Mitrikov
B V
BV
Rodionova
E B
EB
Varlamova
E Iu
EIu
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D018442:Lymphoma, B-Cell, Marginal Zone / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D020551:Pulse Therapy, Drug; D000069283:Rituximab; D012472:Salivation / Q000187:drug effects*; D012859:Sjogren's Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013363:Submandibular Gland / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D005938:Glucocorticoids; D007155:Immunologic Factors; D000069283:Rituximab; D003520:Cyclophosphamide; D008775:Methylprednisolone